Dr. Schiller has devoted her life's work to lung cancer patients and research that may help to prolong their lives, and in some cases, cure them. She has authored more than 20 articles describing phase I clinical trials, indicating her keen interest in trying to bring more agents to her patients' bedsides. She was involved in the studies that brought the first targeted therapy for lung cancer and was an instrumental member of the team that found bevacizumab significantly enhances overall survival in non-small cell lung cancer patients treated with chemotherapy.
She has served in a number of positions at the National Cancer Institute, including as chair of the thoracic committee of the Eastern Cooperative Oncology Group (ECOG), as a member of the Lung Cancer Progress Review Group and the subsequent Lung Cancer Integration and Implementation team. In 2001, Dr. Schiller founded the National Lung Cancer Partnership to raise private funds for lung cancer research and raise awareness of the disease in the broader community in order to improve patient outcomes. Dr. Schiller is active as president of the Partnership's board of directors.
